Healthy ROI on cancer drugs for pharma

It’s much cheaper to develop cancer drugs than pharmaceutical companies claim, say the authors of a new analysis. According to the analysis of R&D costs associated with ten new cancer medicines and subsequent revenue earned, the return on investment is of a magnitude not seen in other industries. The US study found the median R&D cost for ...

Already a member?

Login to keep reading.

© 2021 the limbic